CI:NYSE

The Cigna Group (CI) is trading at $269.66, well below its 20‑day SMA of $285.62 and the 200‑day SMA of $290.20, indicating a potential mean‑reversion opportunity. The RSI of 37.7 suggests the stock is approaching oversold territory, while the MACD remains bearish, signaling short‑term momentum weakness. Volume is increasing, providing liquidity support as the price hovers just above the identified support level of $264.47. Despite the technical softness, the company delivered Q4 earnings that beat expectations, with non‑GAAP EPS of $8.08 versus the consensus $7.88, and posted a 10.4% revenue growth year‑over‑year. Analysts maintain a “Buy” consensus with a median target of $334.5, implying roughly 24% upside from current levels. The dividend yield of 2.3% and a modest payout ratio of 27% underscore a sustainable income stream. The firm’s balance sheet shows ample cash ($8.73 B) against debt ($31.46 B) with a debt‑to‑equity of 75%, and strong free cash flow of $9.77 B. Forward earnings estimates rise to $33.46 per share, driving a forward P/E of 8.1, well below the industry average of 25.4, highlighting a value tilt. A planned CEO succession to Brian Evanko is slated for July 2026, offering continuity in leadership. Overall, the stock combines defensive sector traits, attractive valuation metrics, and a solid dividend, positioning it for potential upside as market sentiment improves.